Desarrollo de Fármacos

Área de la Ciencia:

• Neuroscience; Pharmacology; Genetics

Sus antecedentes:

• Alzheimer's disease (AD) involves amyloid plaques and tau tangles.; Apolipoprotein E4 (ApoE4) is a major genetic risk factor for sporadic AD.; ApoE4 represses Sirtuin 1 (SirT1), a crucial neuroprotective protein, exacerbating AD progression.

Objetivo del estudio:

• Discover and preclinically evaluate DDL-218, a small-molecule SirT1 enhancer.; Target ApoE4 to reverse its repressive effects on SirT1 expression.; Assess DDL-218's therapeutic potential for Alzheimer's disease.

Principales métodos:

• High-throughput screening identified SirT1 enhancer candidates.; Medicinal chemistry and in silico modeling optimized lead compounds.; In vitro and in vivo studies in ApoE4-expressing neuronal cells and AD mouse models were performed.; Mechanisms were investigated using proteomics, chromatin immunoprecipitation, and qRT-PCR.

Principales resultados:

• DDL-218 increased SirT1 protein and mRNA by upregulating NFYB and PRMT5.; Drug treatment displaced ApoE4 from the SirT1 promoter, boosting SirT1 expression.; DDL-218 improved memory in AD mouse models and enhanced brain SirT1, NFYB, and PRMT5 mRNA.; Proteomics indicated upregulation of neuronal function proteins like PTprn2; DDL-218 demonstrated brain penetration and safety.

Conclusiones:

• DDL-218 effectively enhances SirT1 by counteracting ApoE4, showing therapeutic promise for AD.; The compound improved cognition and neural pathways in preclinical AD models.; Further research is warranted to establish DDL-218's targets, mechanism, and efficacy in diverse ApoE4-related AD models.